MINI FUTURE LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:53:49 25/06/2024 BST | ||
| 29.3 EUR | -0.51% |
|
| Current month | +6.58% | ||
| 1 month | +6.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 29.3 | -0.51% |
| 24/06/24 | 29.45 | +1.45% |
| 21/06/24 | 29.03 | -0.55% |
| 20/06/24 | 29.19 | +2.06% |
| 19/06/24 | 28.6 | -0.38% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 08:53 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MD5NTJ |
| ISIN | DE000MD5NTJ3 |
| Date issued | 28/06/2022 |
| Strike | 159.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.29 € |
|---|---|
| Lowest since issue | 13.28 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
465.5
USD
Spread / Average Target
-1.75%
- Stock Market
- Certificates
- Certificat
